Filing Summary: Marathon Patent Group, Inc. (FY2014 Form 10-K)
Period and issuer: This filing covers the fiscal year ended December 31, 2014, with 2013 comparisons. It is an annual report, not a quarterly filing. The filing names the issuer Marathon Patent Group, Inc.; the request metadata’s “MARA Holdings, Inc.” does not match the issuer name in the document.
Business context
The company acquired patent rights and sought to monetize them through licensing and enforcement litigation. By year-end it reported 378 U.S. and foreign patents and patent rights and 22 patent applications, up from 118 patent assets at year-end 2013. Revenue was entirely from patent enforcement activity, generally through one-time settlement and license agreements.
Financial performance and position
| Metric | FY2014 / Dec. 31, 2014 | FY2013 / Dec. 31, 2013 |
|---|---|---|
| Revenue | $21.40 million | $3.42 million |
| Cost of revenue | $11.79 million | $0.96 million |
| Gross profit and margin | $9.62 million; approximately 44.9% | $2.46 million; approximately 72.0% |
| Operating loss | $6.21 million | $3.68 million |
| Net loss | $1.88 million | $3.45 million |
| Net loss attributable to common shareholders | $3.15 million; $0.27 per share per MD&A | $3.45 million; $0.37 per share per MD&A |
| Cash and cash equivalents | $5.08 million | $3.61 million |
| Operating cash flow | $4.45 million provided | $1.52 million used |
| Investing cash flow | $7.87 million used | $3.00 million used |
| Financing cash flow | $4.89 million provided | $5.78 million provided |
| Net working capital | Deficit of $14.79 million | Surplus of $3.88 million |
| Reported indebtedness | $22.49 million | No comparable year-end debt amount stated in the supplied filing text |
Revenue rose 526%, but cost of revenue increased faster, and gross margin fell materially. Operating expenses were $27.61 million, including $5.53 million of patent amortization and a $2.14 million CyberFone goodwill impairment. The $4.91 million income tax benefit reduced the reported net loss; the filing records a $4.95 million net deferred tax asset. Total assets were $59.49 million and total liabilities were $35.23 million at year-end.
Material changes and unusual items
- Five licenses to two licensees represented approximately 88% of 2014 revenue. Clouding contributed $10.5 million, or about 49% of revenue. In 2013, five licenses from one subsidiary represented approximately 62% of revenue.
- Patent acquisitions expanded the portfolio substantially and drove higher amortization, enforcement costs, acquisition obligations, and financing needs. Patent purchases used $7.82 million of cash in 2014.
- Goodwill impairment of $2.14 million related to CyberFone followed a reduced assessment of expected recoveries from remaining defendants.
- The company issued $5.55 million of convertible notes in October 2014 at 11% annual interest, with maturity in 2018, and incurred $543,283 of interest expense in 2014.
- A 2-for-1 stock dividend was declared in November and distributed in December 2014; share and per-share amounts in the filing are generally retroactively adjusted.
Outlook, financing, risks, and contingencies
- Management outlook: Management said year-end cash, expected operating cash flow, and the Fortress financing arrangement were expected to fund operations at least through March 2016. This is not a revenue or earnings forecast, and management cautioned that additional capital could be needed sooner.
- Fortress financing after year-end: On January 29, 2015, the company issued $15 million of senior secured notes to DBD Credit Funding, an affiliate of Fortress, and granted equity and monetization-proceeds rights. The company could require an additional $5 million subject to milestones; a further $30 million was contemplated but not committed. The notes bear cash interest at LIBOR plus 9.75%, with 2.75% paid in kind. The filing describes a $1 million minimum unrestricted-cash covenant and a $15 million monetization-revenue requirement over four specified fiscal quarters. The notes are secured by company assets, with specified exclusions, and impose restrictive covenants.
- Debt and liquidity: The filing reports indebtedness of $29.49 million as of March 18, 2015, versus $22.49 million at December 31, 2014. Negative working capital and acquisition-related payment obligations increase reliance on successful monetization and financing.
- Business risks: Revenue timing and amounts are unpredictable; enforcement is costly and outcomes uncertain. Patent validity challenges, inter partes reviews involving patents from nine portfolios, legal or regulatory changes, competition, and the risk that acquired portfolios fail to generate sufficient recoveries could impair results.
- Legal matters: The company had approximately 77 active defendants in patent enforcement actions at year-end. A former vendor, Dominion Harbor Group, sought more than $3 million in a dispute moved to binding arbitration; the company denied the claims and asserted a counterclaim for approximately $462,000.
- Related parties: The filing describes patent acquisitions, service arrangements, and revenue-sharing relationships involving IP Nav and entities associated with Erich Spangenberg, a significant company affiliate. These include contingent seller payments and participation in recoveries.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing material weaknesses in internal audit resources and segregation of duties. The auditors gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- Other: The company did not hedge foreign-currency exposure and reported a $388,357 foreign-currency translation loss in other comprehensive income. The filing provides no formal forward revenue or earnings guidance.
Most important facts for investors to verify
- Reconcile the reported loss per share: the MD&A cites $0.27 per share attributable to common shareholders, while the financial statements separately show $0.16 per share for continuing operations.
- Review the concentration and collectability of licensing revenue, especially the dependence on a small number of licensees and portfolios.
- Confirm current debt balances, repayment schedules, interest costs, collateral and compliance with Fortress covenants, including the monetization-revenue and minimum-liquidity tests.
- Assess the assumptions supporting the $4.95 million deferred tax asset and its expected realization.
- Evaluate acquisition-related earn-outs, contingent recovery shares, related-party terms, and the remaining MedTech and other payment obligations.
- Track litigation outcomes, patent challenges and impairment indicators, as well as management’s remediation of the disclosed control weaknesses.